Does targeting of the MAPK and AKT pathways in conjunctival melanoma show potential synergy?
ERK and AKT are constitutively activated in conjunctival nevi, PAM and melanoma. While BRAF inhibitors prohibited cell growth, they were not always cytotoxic. Combining MEK and AKT inhibitors led to more growth inhibition and cell death in CM cells. The combination may benefit patients suffering from metastatic conjunctival melanoma.
Direct coronary stenting yielded excellent results at 30 days although some expanded indications will be included.